Document is current
Any future updates will be listed below
-
Authors
Egeler, M. D.
Boomstra, E.
Rohaan, M. W.
Van den Heuvel, N. M. J.
Fraterman, I.
Delfos, M.
van de Poll-Franse, L. V.
Borch, T. H.
Svane, I. M.
Haanen, J. B. A. G.
Retèl, V. P.
Boekhout, A. H.
- License Information
-
More Information
Article History
Received: 14 March 2023
Accepted: 16 August 2023
First Online: 22 August 2023
Declarations
:
: JBAG Haanen: Achilles Therapeutics, BioNTech, BMS, CureVac, Gadeta, Immunocore, Iovance Bio, Instil Bio, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Scenic, Seattle Genetics, Third Rock Ventures, T-Knife (consultant/advisor). IM Svane: IO biotech, Merck, Novartis, Pierre Fabre (consultant/advisor). All other authors declare no competing interests (MD Egeler, E Boomstra, MW Rohaan, NMJ Van den Heuvel, I Fraterman, M Delfos, LV van de Poll-Franse, TH Borch, IM Svane, JBAG Haanen, VP Retèl, AH Boekhout).
